Literature DB >> 20676643

Current, new and future treatments of osteoporosis.

Pooneh Salari Sharif1, Mohammad Abdollahi, Bagher Larijani.   

Abstract

Osteoporosis as a common chronic disease is challenging human health. Although different therapeutic options are routinely used for prevention/treatment of osteoporosis, their side effects and benefits are under question. Increasing our knowledge about signaling pathways in bone and osteocytes as well as osteoblasts and osteoclasts will help us in designing new therapeutic modalities for osteoporosis. In the present study, all new therapeutic measures of osteoporosis have been reviewed. For this purpose, search engines like Pubmed, Web of Science, Scopus, Google Scholar were searched and all relevant articles were found. The study was limited to the year 1998-2010. Bisphosphonates are the cornerstone of osteoporosis treatment, but there are not enough relevant studies that investigated their equivalencies in comparison with each other or the other medications. Therefore, medication selection is empirical and subjective. Furthermore, no eminent study has compared certain combinations. There are new hopes for treatment of osteoporosis, which are more specific with less harm. Our results show that new and emerging therapies are more potent and target specified which more individualize osteoporosis treatment; however, more investigations on their safety and efficacy in comparison with current medications are highly recommended.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20676643     DOI: 10.1007/s00296-010-1586-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  141 in total

1.  Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice.

Authors:  J Cornish; K E Callon; U Bava; D H Coy; T B Mulvey; M A Murray; G J Cooper; G J Cooper; I R Reid
Journal:  J Endocrinol       Date:  2001-07       Impact factor: 4.286

2.  Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.

Authors:  B D Gelb; G P Shi; H A Chapman; R J Desnick
Journal:  Science       Date:  1996-08-30       Impact factor: 47.728

3.  Role of muscle-derived growth factors in bone formation.

Authors:  M W Hamrick; P L McNeil; S L Patterson
Journal:  J Musculoskelet Neuronal Interact       Date:  2010-03       Impact factor: 2.041

Review 4.  Update of current therapeutic options for the treatment of postmenopausal osteoporosis.

Authors:  Solomon Epstein
Journal:  Clin Ther       Date:  2006-02       Impact factor: 3.393

5.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Authors:  Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

6.  Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study.

Authors:  S Ljunghall; P Gärdsell; O Johnell; K Larsson; E Lindh; K Obrant; I Sernbo
Journal:  Calcif Tissue Int       Date:  1991-07       Impact factor: 4.333

7.  Targeting the Wnt signaling pathway to augment bone formation.

Authors:  Mohammad Shahnazari; Wei Yao; Maripat Corr; Nancy E Lane
Journal:  Curr Osteoporos Rep       Date:  2008-12       Impact factor: 5.096

8.  The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation.

Authors:  Naibedya Chattopadhyay; Stephen J Quinn; Olga Kifor; Chianping Ye; Edward M Brown
Journal:  Biochem Pharmacol       Date:  2007-04-27       Impact factor: 5.858

9.  Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy.

Authors:  Wendy Potts; Jonathan Bowyer; Huw Jones; David Tucker; Anthony J Freemont; Andrew Millest; Colin Martin; Wendy Vernon; Diane Neerunjun; Gillian Slynn; Fiona Harper; Rose Maciewicz
Journal:  Int J Exp Pathol       Date:  2004-04       Impact factor: 1.925

10.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

View more
  20 in total

Review 1.  Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors.

Authors:  Armen Yuri Gasparyan; Lilit Ayvazyan; Heather Blackmore; George D Kitas
Journal:  Rheumatol Int       Date:  2011-07-29       Impact factor: 2.631

2.  Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.

Authors:  L Jacob; M Dreher; K Kostev; P Hadji
Journal:  Osteoporos Int       Date:  2015-10-30       Impact factor: 4.507

3.  Osteoporotic fracture and parathyroid hormone.

Authors:  Nabanita S Datta
Journal:  World J Orthop       Date:  2011-08-18

Review 4.  Osteoporosis and fracture risk in people with schizophrenia.

Authors:  Taishiro Kishimoto; Marc De Hert; Harold E Carlson; Peter Manu; Christoph U Correll
Journal:  Curr Opin Psychiatry       Date:  2012-09       Impact factor: 4.741

5.  Reciprocal regulation of adipocyte and osteoblast differentiation of mesenchymal stem cells by Eupatorium japonicum prevents bone loss and adiposity increase in osteoporotic rats.

Authors:  Min-Ji Kim; Woo-Seok Jang; In-Kyoung Lee; Jong-Keun Kim; Ki-Seung Seong; Cho-Rong Seo; No-Joon Song; Min-Hyuk Bang; Young Min Lee; Haeng Ran Kim; Ki-Moon Park; Kye Won Park
Journal:  J Med Food       Date:  2014-06-13       Impact factor: 2.786

6.  Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.

Authors:  G A Otaify; M S Aglan; M M Ibrahim; M Elnashar; R A S El Banna; S A Temtamy
Journal:  Osteoporos Int       Date:  2015-07-03       Impact factor: 4.507

7.  Ibandronate and ventricular arrhythmia risk.

Authors:  Ingrid M Bonilla; Pedro Vargas-Pinto; Yoshinori Nishijima; Adriana Pedraza-Toscano; Hsiang-Ting Ho; Victor P Long; Andriy E Belevych; Patric Glynn; Mahmoud Houmsse; Troy Rhodes; Raul Weiss; Thomas J Hund; Robert L Hamlin; Sandor Györke; Cynthia A Carnes
Journal:  J Cardiovasc Electrophysiol       Date:  2013-12-20

8.  The functional mechanism of simvastatin in experimental osteoporosis.

Authors:  Lifen Dai; Ming Xu; Haiying Wu; Lanjie Xue; Dekai Yuan; Yuan Wang; Zhiqiang Shen; Hongbin Zhao; Min Hu
Journal:  J Bone Miner Metab       Date:  2014-12-17       Impact factor: 2.626

9.  Sulfuretin induces osteoblast differentiation through activation of TGF-β signaling.

Authors:  No-Joon Song; So-Mi Kwon; Suji Kim; Hyang-Jin Yoon; Cho-Rong Seo; Byunghyun Jang; Seo-Hyuk Chang; Jin-Mo Ku; Jeong-Soo Lee; Ki-Moon Park; Joung-Woo Hong; Geun Hyung Kim; Kye Won Park
Journal:  Mol Cell Biochem       Date:  2015-08-11       Impact factor: 3.396

10.  The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits.

Authors:  Huan Zhou; Yunqiu Xie; Zulqarnain Baloch; Qingping Shi; Qiang Huo; Tao Ma
Journal:  J Bone Miner Metab       Date:  2016-04-27       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.